




La recherche en santé : nouveaux modèles, nouveaux leviers

Ruxandra Draghia-Akli, MD, PhD
Directrice Santé
DG Recherche et Innovation

HORIZON 2020

Rencontres du G5 santé; Paris, 18 Novembre 2014



Health, Demographic change and wellbeing - challenges ahead

- Chronic and degenerative diseases gain importance in the context of the ageing population
- Health expenditure at 10% of GDP - more than 70% of healthcare spending on chronic diseases

= > Need for innovation and transformation of health care interventions and health systems and services

EU must catch up with global health innovation leaders and keep its biomedical industry

FP7 Health Cooperation programme

Key figures

6.1 € billion invested

1,050 projects

11,000 teams

3,500 organisations

130 countries

First outcomes

(on 370 closed projects)

230 patent applications

34 spin-offs

12,500 publications

8 average publication IF

1004 collaborative projects in health research from 2007-13



NanoMal project - malaria, now, Dengue, Chagas or yellow fever, soon!



Horizon 2020 'Health, demographic change and wellbeing'


**Translate science into benefit
for citizens**

Improve health outcomes



**Support a competitive health
and care sector**

**Promote healthy and active
ageing**

Funding for Health/Biotech in H2020



New approaches and new means for supporting health research and innovation at EU-level



Collaborative research



€1.2 billion for the Work Programme 2014/15


Challenge-driven

Broad topics, bottom-up approach

Spotlight on 'personalising health and care' and 'coordination'

Strong focus on end users

Innovative Medicines Initiative 2



IMI 2:
~€3.2 billion
EC: €1.6b ;
EFPIA (€1.4b)- other (€0.2b)

- Coverage of the entire medical research and innovation value chain
- Strategic Research Agenda based on the WHO Priority Medicine Report renewed in July 2013
- Involve life science industries other than pharmaceuticals (diagnostics, imaging, animal health, ICT, ...)
- **World class research and innovation leading to breakthrough vaccines, medicines and treatments**

Innovative Medicines Initiative 2

First Call:

Type 1 diabetes

Retinal diseases

Deadline for submission: 12 November 2014

Second Call: Ebola

Deadline for submission: 1 December 2014

Third/Forth Call:

Research and Innovation Actions:

- Assessing Risk and Progression of Pre-diabetes and Type 2 Diabetes to Enable Disease Modification (SGG Diabetes)
- Towards a Quantitative Biological Approach for Neuropsychiatry
- Programme on Remote Assessment of Disease and Relapse (RADAR) (SGG Data & Knowledge Management)
- Enabling Patient-Centered Medicine Development through a Patient-Inspired Knowledge Hub (PIKH) (SGG Data & Knowledge Management)
- Consistency of Approach for Vaccines Quality Testing (SGG Infections Control)
- Pertussis Vaccines (SGG Infections Control)

Coordination and Support Action:


- Medicines Adaptive Pathways to Patients (ex-SGG MAPPs)

Deadline for submission: March-April 2015

HORIZON 2020



EDCTP 2



EDCTP 2:
~€1.37 Billion
EC: €683m – Member States: €683m

- **Almost €700 million EU co-funding, match the same member states contribution**

Broader scope:
including HIV, TB, malaria, neglected infectious diseases, all clinical phases, diagnostics and delivery optimisation

Longer duration:
10 years

EDCTP Association established in April 2014*

EDCTP2 launch : 2 December 2014, Cape Town

HORIZON 2020

* Cameroon, Congo (Brazzaville), The Gambia, Ghana, Mozambique, Niger, Senegal, South Africa, Tanzania, Uganda, Zambia
Austria, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Switzerland (as so-called 'aspirant member'), the United Kingdom





Active and Assisted Living 2

AAL 2:
~€700 million
EC: €175m – Member States: €175m
Industry: €350m



More EU funding of up to €175 million

Participating countries pay €175 million

Additional contribution of €350 million from industrial partners

Market-oriented ICT research in assisted living technologies and services

New instruments e.g. prizes and innovation grants



General opening


- Horizon 2020 is open to participation from across the world
- Automatic funding:
 - Member States (including overseas departments and overseas territories)
 - Associated Countries
 - Exhaustive list of countries in annex to work programme (BRIC + Mexico no longer in this list!)
- Participants from other countries funded in exceptional cases:
 - when provision is made in the call text
 - bilateral agreement (e.g. health challenge – NIH)
 - when the Commission deems it essential (case by case assessment)
- **Program level cooperation**



HORIZON 2020



SME instrument




Financial instruments

H2020:
~€2.8 billion

- **InnovFin Large Projects**
 - Loans from €7.5 m to €300 m; delivered directly by EIB
- **InnovFin MidCap Growth Finance**
 - Loans from €7.5 m to €25 m; delivered directly by EIB
- **InnovFin MidCap Guarantee**
 - Guarantees to financial intermediaries (banks, etc.)
 - Loans from €7.5 m to €25 m; implemented by EIB
- **InnovFin SME Guarantee**
 - Guarantees / counter-guarantees to financial intermediaries
 - Loans from €25,000 to €7.5 m; implemented by EIF
- **InnovFin Advisory**
 - Improve 'bankability' of large projects

Financial instruments: how it works



Innovation inducement prizes



'This technology could save lives – exactly the type of innovation an EU inducement prize should support'

Máire Geoghegan-Quinn, European Commissioner for Research and Innovation

Ability to respond quickly to emerging challenges: Ebola

- **On-going Ebola Research – FP7 projects:** using flexibility within on-going projects
- **' Ebola Exceptional Procedure' – Horizon 2020:** first time ever use of provisions in Financial Regulation (art 128) and its Rules of application (art 190) to award grants without a call for proposals *"in exceptional and duly substantiated emergencies"*

EbolaVac: coordinator GlaxoSmithKline (BE) Phase II clinical trials in Europa and Africa on most advanced vaccine candidate ChAd3-EBOV (trials to start in November in WHO and humanitarian aid org. and in January in Mali, Cameroon, Ghana and Nigeria) – EU funding €15.2m

REACTION: coordinator INSERM (FR) Safety and efficacy of favipiravir (licensed for influenza) in animal model and in phase I and II studies (trials to start in December) – EU funding €2.6m

Ebola_Tx: Prins Leopold Instituut for Tropische Geneeskunde (BE) Safety, efficacy and feasibility of plasma from survivors of Ebola infection (trials to start in December in Guinea) – EU funding €2.9m

EVIDENT: Bernhard-Nocht Institut für Tropenmedizin (DE) Host-pathogen interaction, transmissibility of the virus in various body fluids and understanding the mutations of the virus – EU funding €1.8m

IF-EBOLa: Institut de Recherche pour le Développement (F) Safety and efficacy of passive immunotherapy by deploying horse serum containing antibodies against Ebola (testing to start mid-2015 in Guinea and Sierra Leone) – EU funding €2.9m

First call in Ebola+ programme on Ebola and other filoviral diseases of the Innovative Medicines Initiative (IMI2)

- ❑ the EU Commission and the EU pharmaceutical industry has launched a **€280 million call for proposals** to boost research on Ebola
- ❑ **€140 million from Horizon 2020** and €140 million from the pharmaceutical companies (members of the EU Federation of Pharmaceutical Industries and Associations - EFPIA).
- ❑ The call for proposals will use **a new fast-track procedure** to get successful projects up and running early next year.
- ❑ Topics in the call address **vaccine development** Phase I, II, and III; Manufacturing capability; Stability of vaccines during transport and storage; Deployment and compliance of vaccination regimens as well as Rapid diagnostic tests
- ❑ More topics to come next year


EDCTP2

- Included Ebola and other emerging pathogens of risk to Africa in its work programme → possibility to fund clinical trials on drugs, vaccines, diagnostics in upcoming calls
- Urge Participating States to increase 2014/2015 budget and coordinate relevant research activities

International collaboration

- WHO
- Bill and Melinda Gates Foundation
- Wellcome Trust
- US, Canada, Australia, South Africa, Brazil , France, Spain, Thailand, Korea via GloPID-R
- Initiated working group under EU Health research programme Committee

Information about all EU funding opportunities on the Participant Portal – your one-stop shop



<http://ec.europa.eu/research/participants/portal>



Thank you !

ruxandra.draghia-akli@ec.europa.eu

HORIZON 2020